Abstract CT418: A Phase Ib study of BKM120 combined with abiraterone acetate for castrate-resistant, metastatic prostate cancer

Oncologic outcome of patients with newly diagnosed metastatic prostate cancer (mPCa) is poor. The treatment paradigm for newly diagnosed mPCa has changed. The standard of care for men with metastatic hormone-naive prostate cancer has been systemic androgen deprivation therapy (ADT). Previous randomized studies demonstrated an overall survival benefit by the addition of early chemotherapy with six cycles of docetaxel. More recently, results from randomized trials also demonstrated a survival benefit by the addition of abiraterone acetate to the ADT in men with metastatic disease. The aim of this review is to summarize the results from most recent studies, including men with newly diagnosed metastatic hormone-naive prostate cancer, focusing on chemotherapy and ADT. This review contains 1 figure, 2 tables, and 47 references. Key Words: abiraterone acetate, androgen deprivation therapy, androgen deprivation, castrate sensitive, chemotherapy, continuous androgen deprivation, docetaxel, hormone-naive, intermittent androgen deprivation, metastatic prostate cancer

Download Full-text

Line of abiraterone acetate in castration-resistant metastatic prostate cancer - Does it matter? report of a multi-institutional experience

Indian Journal of Cancer ◽

10.4103/0019-509x.178379 ◽

2015 ◽

Vol 52 (4) ◽

pp. 658 ◽

Cited By ~ 1

Author(s):

S Gunduz ◽

H Bozcuk ◽

M Yıldız ◽

SS Goksu ◽

M Uysal ◽

...

Keyword(s):

Prostate Cancer ◽

Metastatic Prostate Cancer ◽

Abiraterone Acetate ◽

Castration Resistant ◽

Institutional Experience

Download Full-text

Management of Advanced and Metastatic Prostate Cancer: A Need for a Sub-Saharan Guideline

Journal of Oncology ◽

10.1155/2019/1785428 ◽

2019 ◽

Vol 2019 ◽

pp. 1-9 ◽

Cited By ~ 3

Author(s):

Ayun Cassell ◽

Bashir Yunusa ◽

Mohamed Jalloh ◽

Medina Ndoye ◽

Mouhamadou M. Mbodji ◽

...

Keyword(s):

Prostate Cancer ◽

Androgen Deprivation Therapy ◽

Metastatic Prostate Cancer ◽

Cost Effective ◽

Androgen Deprivation ◽

Sub Saharan Africa ◽

International Agency ◽

Castrate Resistant Prostate Cancer ◽

Sub Saharan ◽

Castrate Resistant

The estimated incidence rate of prostate cancer in Africa was 22.0/100,000 in 2016. The International Agency for Research on Cancer (IARC) has cited prostate cancer as a growing health threat in Africa with approximated 28,006 deaths in 2010 and estimated 57,048 deaths in 2030. The exact incidence of advanced and metastatic prostate cancer is not known in sub-Saharan Africa. Hospital-based reports from the region have shown a rising trend with most patients presenting with advanced or metastatic disease. The management of advanced and metastatic prostate cancer is challenging. The available international guidelines may not be cost-effective for an African population. The most efficient approach in the region has been surgical castration by bilateral orchidectomy or pulpectomy. Medical androgen deprivation therapy is expensive and may not be available. Patients with metastatic castrate-resistant prostate cancer tend to be palliated due to the absence or cost of chemotherapy or second-line androgen deprivation therapy in most of Africa. A cost-effective guideline for developing nations to address the rising burden of advanced prostate cancer is warranted at this moment.

Download Full-text